Eptifibatide

What is Eptifibatide?

Eptifibatide is a synthetic cyclic heptapeptide (Mpr-homoArg-Gly-Asp-Trp-Pro-Cys-NH2, with a disulfide bridge between the mercaptopropionyl and cysteine residues) that acts as a reversible, selective antagonist of the platelet glycoprotein IIb/IIIa (αIIbβ3) integrin receptor. It is FDA-approved (May 1998) under the brand name Integrilin — originally developed by COR Therapeutics (later acquired by Millennium Pharmaceuticals, then by Takeda) in partnership with Schering-Plough — for intravenous antiplatelet therapy in patients with acute coronary syndromes (unstable angina and non-ST-elevation myocardial infarction) and in patients undergoing percutaneous coronary intervention, including those with intracoronary stenting. The molecule's design lineage is unusual: its pharmacophore is the KGD (Lys-Gly-Asp) motif of barbourin, a disintegrin isolated from the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri) by Scarborough and colleagues at COR Therapeutics, who recognized that the KGD sequence — rather than the more common RGD motif found in other disintegrins and integrin ligands — confers selectivity for αIIbβ3 over the closely related αvβ3 integrin. Eptifibatide is the synthetic, conformationally constrained, KGD-mimetic distillation of that biology. It binds to the fibrinogen-recognition pocket on activated GP IIb/IIIa with rapid on- and off-kinetics, blocking the final common pathway of platelet aggregation, with a plasma half-life of approximately 2.5 hours and primary renal clearance.

What Eptifibatide Is Investigated For

Eptifibatide has two FDA-approved settings — non-ST-elevation acute coronary syndromes (NSTE-ACS) and PCI — and a meaningful set of off-label uses centered on procedural bailout and short-acting antiplatelet bridging. The pivotal evidence is from three large randomized trials. PURSUIT (NEJM 1998) randomized 10,948 NSTE-ACS patients and showed a modest but statistically significant reduction in the 30-day composite of death or non-fatal MI (14.2% vs. 15.7%) with eptifibatide added to standard therapy. IMPACT-II (Lancet 1997) established procedural benefit in 4,010 patients undergoing PCI, and ESPRIT (Lancet 2000) demonstrated that a higher-dose double-bolus regimen (180 mcg/kg bolus repeated at 10 minutes plus 2 mcg/kg/min infusion) reduced 48-hour ischemic events by approximately 35% in elective stenting, with the benefit preserved at 1 year (JAMA 2002). The honest synthesis is that eptifibatide's role has narrowed substantially in the contemporary era. The widespread adoption of potent oral P2Y12 inhibitors (prasugrel, ticagrelor) and routine use of bivalirudin or heparin monotherapy has displaced GP IIb/IIIa inhibitors from upstream NSTE-ACS use into a primarily bailout role for thrombotic complications during PCI. The EARLY ACS trial (NEJM 2009) tested early routine eptifibatide vs. delayed provisional use in 9,492 NSTE-ACS patients and found no benefit of upfront use — driving the contemporary 'use only when needed' posture. Eptifibatide remains a useful tool for procedural rescue (visible thrombus, slow flow, no-reflow) and is the most commonly used GP IIb/IIIa inhibitor in US cath labs by virtue of its favorable pharmacokinetic profile compared to abciximab and tirofiban — short half-life, reversible binding, and renal clearance that allows controlled offset.

History & Discovery

Eptifibatide's discovery story is one of the more elegant examples of venom-to-drug pharmacology in modern cardiology. The molecular lineage begins with viper venom biology. Snake venoms have been recognized since the early 20th century to disrupt mammalian hemostasis, and by the 1980s the responsible molecules — disintegrins — were beginning to be isolated and characterized. Disintegrins are small (40-100 amino acid) cysteine-rich peptides that contain integrin-recognition motifs (most commonly RGD) and disrupt integrin-ligand interactions, including platelet aggregation. The challenge for therapeutic translation was selectivity: most disintegrins cross-react across multiple integrins, producing off-target effects. In 1989, COR Therapeutics was founded in South San Francisco by Vaughn Kailian and others with a focus on cardiovascular drug discovery. Mark Scarborough, a biochemist at COR, led a program to characterize disintegrins from poorly studied North American viper species, hypothesizing that natural diversity might yield molecules with unusual selectivity profiles. In a 1991 J Biol Chem paper (Scarborough et al., 266:9359-9362), the team isolated and characterized barbourin, a 73-amino-acid disintegrin from the venom of the southeastern pygmy rattlesnake Sistrurus miliarius barbouri. Barbourin's distinguishing feature was a KGD (Lys-Gly-Asp) motif in place of the canonical RGD found in most other disintegrins. This single-residue substitution conferred substantially greater selectivity for αIIbβ3 (the platelet integrin) over αvβ3 (the vitronectin receptor) — a critical insight, because αvβ3 selectivity drives off-target effects on endothelium, osteoclasts, and other tissues. The subsequent medicinal-chemistry program (Scarborough et al., J Biol Chem 1993, 268:1066-1073) miniaturized barbourin's biology into a synthetic cyclic peptide. The team systematically explored cyclic heptapeptides containing KGD-like motifs, optimizing the side-chain lengths, ring conformation, and disulfide constraint. The result was eptifibatide: mercaptopropionyl-homoarginine-glycine-aspartate-tryptophan-proline-cysteine amide, with a disulfide bridge cyclizing the molecule. The homoarginine substitution for lysine, the cyclic conformational constraint, and the careful selection of the C-terminal residues delivered subnanomolar αIIbβ3 affinity with >100-fold selectivity over αvβ3 and a synthetically tractable, scalable molecule. Clinical development proceeded rapidly through the early 1990s in partnership with Schering-Plough, which acquired marketing rights. The IMPACT-II trial (Lancet 1997) established procedural benefit in PCI; the PURSUIT trial (NEJM 1998) established the NSTE-ACS indication. The FDA approved Integrilin in May 1998 for both indications. The ESPRIT trial (Lancet 2000) refined the dosing to the now-standard double-bolus regimen and demonstrated durable benefit in elective stenting at 1 year (JAMA 2002). Commercially, COR Therapeutics was acquired by Millennium Pharmaceuticals in 2002 for approximately $2 billion, primarily on the strength of Integrilin revenue. Millennium itself was acquired by Takeda in 2008. Schering-Plough's marketing rights passed through the Merck-Schering merger in 2009. Generic eptifibatide entered the US market in 2015 following patent expiration, and multiple generic manufacturers now supply the global market. Integrilin remains in active clinical use, primarily by Merck. Scientifically, eptifibatide's role has narrowed in the contemporary era. The 2009 EARLY ACS trial (Giugliano et al., NEJM 2009) tested whether routine upstream eptifibatide added benefit to contemporary antiplatelet therapy in NSTE-ACS — and the answer was no, with more bleeding. The widespread adoption of potent oral P2Y12 inhibitors (prasugrel, ticagrelor) and the IV P2Y12 inhibitor cangrelor has further displaced GP IIb/IIIa inhibitors from upstream use. Contemporary cath-lab practice uses eptifibatide primarily for selective bailout — visible thrombus, slow flow, no-reflow — where its rapid onset, potent platelet inhibition, and reversible kinetics still offer real procedural value (Rubboli & Patti, Curr Vasc Pharmacol 2018). The molecule itself remains a textbook example of structure-guided venom-derived drug design and one of the most-prescribed therapeutic peptides in interventional cardiology.

How It Works

When a blood clot forms, platelets stick together by grabbing molecules of fibrinogen using a receptor on their surface called GP IIb/IIIa. Eptifibatide is a small synthetic peptide that fits into that receptor's grip and blocks fibrinogen from binding — the platelets can still be activated by injury or other signals, but they cannot stick to each other. Because every pathway that activates platelets eventually relies on this same final receptor, blocking GP IIb/IIIa is the most powerful antiplatelet effect known. The drug is given as a quick IV bolus plus a continuous drip, and platelet function returns to normal within a few hours of stopping. The molecule itself is modeled on a snake venom protein from the southeastern pygmy rattlesnake — a protein that evolved to disable prey clotting, redesigned by chemists into a precise, reversible human therapeutic.

Eptifibatide is a rationally designed cyclic heptapeptide antagonist of the platelet integrin αIIbβ3 (also called glycoprotein IIb/IIIa, GP IIb/IIIa, or CD41/CD61). Its molecular pharmacology is a story of structure-guided drug design rooted in viper venom biology. The pharmacophore lineage begins with disintegrins — a family of small (40-100 amino acid) cysteine-rich peptides found in viper venoms that disrupt integrin-ligand interactions. Most disintegrins contain an RGD (Arg-Gly-Asp) motif and bind broadly to RGD-recognizing integrins. In 1991, Scarborough and colleagues at COR Therapeutics characterized barbourin, a 73-amino-acid disintegrin from the venom of the southeastern pygmy rattlesnake Sistrurus miliarius barbouri (J Biol Chem 266:9359-9362). Barbourin's distinguishing feature was a KGD (Lys-Gly-Asp) motif in place of the canonical RGD, and it bound αIIbβ3 with substantially greater selectivity than other disintegrins — reducing cross-reactivity with αvβ3 (the vitronectin receptor) that mediates broader integrin biology. This selectivity insight became the seed of eptifibatide's design. In a 1993 J Biol Chem paper (268:1066-1073), Scarborough and colleagues described the rational miniaturization of barbourin into short cyclic peptide antagonists with high specificity for GP IIb/IIIa. The final design, eptifibatide, is a cyclic heptapeptide: mercaptopropionyl-homoarginine-glycine-aspartate-tryptophan-proline-cysteine amide, with a disulfide bond closing the cycle between the mercaptopropionyl and cysteine residues. The homoarginine-glycine-aspartate sequence preserves the KGD-like recognition geometry (with homoarginine substituting for the lysine to optimize the side-chain length and basicity). The cyclic constraint locks the recognition motif into the bound conformation, dramatically increasing affinity over linear analogs. The result is a 832-Da molecule with subnanomolar affinity for activated αIIbβ3 and >100-fold selectivity over αvβ3. Mechanistically, eptifibatide binds to the fibrinogen-recognition pocket on activated αIIbβ3, occupying the site where the γ-chain dodecapeptide of fibrinogen (sequence HHLGGAKQAGDV) and the RGD sequences of fibrinogen, von Willebrand factor, vitronectin, and fibronectin would normally bind. Once the receptor is occupied, fibrinogen cannot bridge adjacent platelets, and platelet aggregation — the final common pathway driven by every upstream activator (thrombin, ADP, thromboxane A2, collagen, epinephrine, serotonin) — is blocked. Single-platelet activation, granule release, and shape change can still occur; what is prevented is the cross-linking that forms an aggregate. Kinetically, eptifibatide is a competitive, reversible antagonist with rapid on- and off-rates. At therapeutic plasma concentrations (~1.5-2 μg/mL during the standard 2 mcg/kg/min infusion following double bolus), platelet aggregation in response to ADP is inhibited by approximately 80%. Steady-state is reached within 4-6 hours of starting the infusion, with ~50% receptor occupancy. The plasma half-life is approximately 2.5 hours, and platelet function recovers within 4-8 hours of discontinuation — substantially faster than abciximab. Approximately 50% of an administered dose is renally excreted, with the remainder cleared via deamidation and other non-renal pathways. The contrast with abciximab is mechanistically informative: abciximab is a non-competitive, slowly reversible antibody Fab fragment that binds with high affinity and slow off-rate, redistributing onto platelet GP IIb/IIIa receptors over many hours. Eptifibatide is a small competitive antagonist with rapid kinetics — pharmacology that allows for tighter procedural titration and faster offset for bleeding management or urgent surgery. The αIIbβ3 receptor itself is a heterodimeric integrin expressed at approximately 80,000 copies per platelet (the most abundant platelet surface protein), with a structurally resolved ligand-binding head domain that has been the target of intensive structural and pharmacologic study, summarized in Huang and colleagues' 2019 αIIbβ3 review (J Hematol Oncol 12:26).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Eptifibatide:

• 01Optimal use in the contemporary era of potent oral P2Y12 inhibitors (prasugrel, ticagrelor) and IV cangrelor — head-to-head comparisons of bailout eptifibatide vs. cangrelor for procedural thrombotic complications have not been adequately powered.
• 02Best dose and infusion duration when paired with bivalirudin rather than heparin — most pivotal trials predate routine bivalirudin use and the optimal combined regimen remains center-specific.
• 03Management of eptifibatide-associated immune thrombocytopenia, including risk of recurrence on re-exposure and choice of alternative GP IIb/IIIa agent if antiplatelet rescue is needed.
• 04Role in primary PCI for STEMI in the contemporary era — declining use as bivalirudin and potent oral P2Y12 inhibitors have displaced upstream GP IIb/IIIa inhibition, but the correct posture for high-thrombus-burden STEMI presentations is still debated.
• 05Pharmacokinetic and clinical evidence base in patients with severe renal impairment short of dialysis is thinner than in normal-renal-function populations, with most pivotal trials having excluded these patients.
• 06Evidence for off-label bridging antiplatelet therapy in stented patients requiring temporary P2Y12 inhibitor discontinuation for non-cardiac surgery is largely observational; randomized data are sparse.
• 07Pediatric use in congenital heart disease and in pediatric coronary intervention is limited to case series; dose-finding and safety data are not robust.

Forms & Administration

Eptifibatide is supplied as a sterile aqueous solution (0.75 mg/mL or 2 mg/mL) in single-use vials for intravenous use, administered as a bolus-plus-infusion regimen by trained cath-lab, ICU, or coronary-care personnel. The standard PCI dose is a 180 mcg/kg IV bolus immediately before the procedure, followed by a second 180 mcg/kg IV bolus 10 minutes after the first (the 'double bolus' regimen established in ESPRIT), with a continuous infusion of 2 mcg/kg/min for up to 18-24 hours post-procedure. The standard NSTE-ACS dose is a single 180 mcg/kg IV bolus followed by 2 mcg/kg/min continuous infusion for up to 72 hours (or up to 96 hours if PCI is performed during the infusion). Dose adjustment is required for renal impairment: in patients with CrCl <50 mL/min, the bolus is unchanged but the maintenance infusion is reduced to 1 mcg/kg/min. Eptifibatide is contraindicated in dialysis patients. Activated clotting time monitoring during PCI follows standard heparin-based protocols; eptifibatide itself does not meaningfully prolong ACT. Platelet count monitoring at baseline, within 6 hours of initiation, and at least daily during infusion is mandatory. This is a prescription-only hospital medication administered under direct physician supervision in a monitored cardiac care setting; it is not suitable for outpatient or self-administered use under any circumstances.

Common Questions

Who Eptifibatide Is NOT For

Drug & Supplement Interactions

Eptifibatide is cleared roughly 50% by the kidneys with the remainder by deamidation and other non-renal pathways, and does not undergo cytochrome P450 metabolism. As a consequence, pharmacokinetic drug-drug interactions mediated by CYP enzymes or hepatic transporters are not expected and no dose adjustment is required for concomitant CYP inhibitors or inducers. The dominant interactions are pharmacodynamic and involve additive bleeding risk with other antithrombotics. Concurrent administration with anticoagulants (unfractionated heparin, low-molecular-weight heparins, fondaparinux, bivalirudin, warfarin, direct oral anticoagulants) is part of the intended treatment paradigm in ACS and PCI — eptifibatide is essentially never used as monotherapy — but the bleeding burden is additive and requires careful dose management and monitoring. The PURSUIT and ESPRIT regimens were designed around concurrent heparin with target ACT in defined ranges, and contemporary practice typically pairs eptifibatide with weight-adjusted heparin or bivalirudin. Concurrent use with thrombolytic agents (alteplase, tenecteplase, reteplase) substantially increases intracranial hemorrhage risk and is generally avoided. The historical combination of GP IIb/IIIa inhibitors plus reduced-dose fibrinolytics for facilitated PCI was abandoned after trials showed excess bleeding without clear ischemic benefit. Oral antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) are routinely used concurrently — this is the standard ACS and PCI antiplatelet stack. The bleeding burden again adds; in the contemporary era of potent oral P2Y12 inhibitors, the marginal benefit of adding eptifibatide upstream has narrowed substantially (EARLY ACS), driving the shift to selective bailout use. NSAIDs, SSRIs, and herbal anticoagulants (ginkgo, high-dose fish oil) can additively increase bleeding risk in the procedural period, though clinical significance in a supervised inpatient setting is usually modest. As always, the operative reference for specific dose-adjustment and interaction guidance is the institutional protocol and the current FDA prescribing information, not this summary.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions